Expression Therapeutics Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Expression Therapeutics's estimated annual revenue is currently $3.4M per year.(i)
  • Expression Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Expression Therapeutics has 22 Employees.(i)
  • Expression Therapeutics grew their employee count by 0% last year.

Expression Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
VP ManufacturingReveal Email/Phone
4
Director Gene Therapy and Blood DisordersReveal Email/Phone
5
Director GMPReveal Email/Phone
6
Director OncologyReveal Email/Phone
7
Senior Manager Vector ManufacturingReveal Email/Phone
8
R&D ManagerReveal Email/Phone
9
Senior Manager for Primary Immunodeficiencies ProgramReveal Email/Phone
10
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$1.7M11-8%N/AN/A
#3
$2.3M1550%N/AN/A
#4
$1.1M70%N/AN/A
#5
$17.1M1105%$0.07BN/A
#6
$4M26-7%N/AN/A
#7
$0.8M50%N/AN/A
#8
$1.1M717%N/AN/A
#9
$7.8M502%N/AN/A
#10
$1.7M1110%N/AN/A
Add Company

What Is Expression Therapeutics?

Expression Therapeutics is a biotechnology company based in Atlanta. Our therapeutic pipeline includes advanced gene therapies for hemophilia A and B; neuroblastoma, T-cell leukemia/lymphoma, and acute myeloid leukemia (AML); and hematologic disorders such as hemophagocytic lymphohistiocytosis (HLH). Each product candidate has been specifically engineered using proprietary gene expression biotechnologies designed for optimal safety and efficacy. Our mission is to develop novel gene therapies that will dramatically improve the lives of patients.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.9M2210%N/A
#2
$2.2M22N/AN/A
#3
$3.2M22N/AN/A
#4
$2.2M22N/AN/A
#5
$2.2M22N/AN/A